Aedifica proposes EUR300m asset disposal to secure merger approval

Aedifica has proposed divesting approximately EUR300 million in assets, representing 10% of the combined entity's Belgian portfolio, to address Belgian Competition Authority (BCA) concerns regarding its pending merger. This significant disposal, which exceeds market expectations according to Kepler, pushes the merger approval timeline to January 2026. Kepler notes this delay is a setback likely to sustain pressure on Aedifica's share price, which has already underperformed the EPRA index since the merger announcement.

Analysis

Aedifica has proposed divesting approximately EUR300 million in assets, representing 10% of the combined entity's Belgian portfolio, to address concerns from the Belgian Competition Authority (BCA) regarding its pending merger. This significant commitment follows additional questions from the BCA's investigation service, indicating regulatory hurdles for the transaction.

The proposed EUR300 million disposal exceeds market expectations, according to Kepler, yet the investment firm highlights continued uncertainty regarding deal approval. This regulatory delay pushes the merger timeline to January 2026, eliminating previous hopes for a Q4 2025 close.

Kepler views this extended timeline as "another setback" likely to sustain pressure on Aedifica's share price. The stock has already underperformed the EPRA index by approximately 10% in total return terms since the initial merger announcement, reflecting ongoing investor apprehension. The moderately negative sentiment and pessimistic tone surrounding the news underscore the market's cautious outlook.

Key Decisions for Investors

• Investors should closely monitor the BCA's final decision, expected within 55 working days, as approval or rejection will significantly impact the merger's viability and Aedifica's strategic direction.
• Evaluate Aedifica's valuation considering the EUR300 million asset disposal and the potential impact on future earnings and portfolio quality, especially given the stock's recent underperformance.
• Factor in the heightened regulatory risk associated with large M&A transactions in the healthcare real estate sector, as delays and required divestments can erode deal value and extend uncertainty.